International Journal of Stem Cells : eISSN 2005-5447

Table. 2.

Table. 2.

Patients characteristics by RIFLE classifications of AKI (n=70)

VariablesNo AKI (n=41)Median±SD or n (%)Risk (n=8)Median±SD or n (%)Injury (n=9)Median±SD or n (%)Failure (n=2)Median±SD or n (%)p value
Age (n=70)35±12.227±9.433±7.621±1.4NS
Gender
 Male (n=36)25 (61%)4 (50%)6 (66.7%)1 (50%)NS
 Female (n=24)16 (39%)4 (50%)3 (33.3%)1 (50%)
Chemotherapy
 Cyclophosphamide 50~60 mg/kg+Fludarabine 30~35 mg/m2±ATG 3 mg/kg3 (7.3%)1 (12.5%)01 (50%)0.02
 Melphalan 180 mg/m225 (61%)1 (12.5%)2 (22.2%)0
 Melphalan 80~130 mg/m2+Fludarabine 30~35 mg/m25 (12.2%)4 (50%)1 (11.1%)0
 Melphalan 180 mg/m2+VP-16 700~1200 mg OR Fludarabine 90~150 mg7 (17.1%)2 (25%)5 (55.6%)1 (50%)
 Other (miscellaneous1 (2.4%)01 (11.1%)0
HSCT type (n=60)
 Auto22 (53.7%)001 (50%)<0.001
 Allo19 (46.3%)8 (100%)9 (100%)1 (50%)
BMI25.7±4.527±8.324±5.530.5±10.6NS
BSA1.8±0.181.7±0.21.7±0.21.8±0.19NS
Donor gender (Allo=44)
 Male16 (39%)6 (75%)9 (100%)1 (50%)0.01
 Female5 (7.3%)2 (25%)01 (50%)
Medical diagnosis
 Malignancies11 (26.8%)2 (25%)2 (22.2%)1 (50%)NS
 Non-malignancies30 (73.2%)6 (75%)7 (77.8%)1 (50%)
Nephrotoxic drugs
 Nephrotoxic drugs32 (78%)6 (75%)7 (77.8%)2 (100%)NS
 No nephrotoxic drugs7 (18%)2 (14.3%)1 (11.1%)0
 Unknown cases2 (4.9%)01 (11.1%)0
Blood urea nitrogen25.5±11.732±15.941.4±3.5127.8±600.000
Survival rate
 Survived23 (77%)4 (67%)3 (38%)00.09
 Deceased7 (23.3%)2 (33.3%)5 (63%)1 (100%)
International Journal of Stem Cells 2019;12:43-50 https://doi.org/10.15283/ijsc18056
© 2019 International Journal of Stem Cells